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Purpose: The nationwide public health registers in Denmark provide a unique opportunity for 
evaluation of disease-associated morbidity if the positive predictive values (PPVs) of the primary 
diagnosis are known. The aim of this study was to evaluate the predictive values of hemolytic 
anemias registered in the Danish National Patient Register.
Patients and methods: All patients with a first-ever diagnosis of hemolytic anemia from either 
specialist outpatient clinic contact or inpatient admission at Odense University Hospital from 
January 1994 through December 2011 were considered for inclusion. Patients with mechanical 
reason for hemolysis such as an artificial heart valve, and patients with vitamin-B12 or folic 
acid deficiency were excluded.
Results: We identified 412 eligible patients: 249 with a congenital hemolytic anemia diag-
nosis and 163 with acquired hemolytic anemia diagnosis. In all, hemolysis was confirmed in 
359 patients, yielding an overall PPV of 87.1% (95% confidence interval [CI]: 83.5%–90.2%). 
A diagnosis could be established in 392 patients of whom 355 patients had a hemolytic diagnosis. 
Diagnosis was confirmed in 197 of the 249 patients with congenital hemolytic anemia, yielding 
a PPV of 79.1% (95% CI: 73.5%–84.0%). Diagnosis of acquired hemolytic anemia could be 
confirmed in 136 of the 163 patients, resulting in a PPV of 83.4% (95% CI: 76.8%–88.8%). 
For hemoglobinopathy PPV was 84.1% (95% CI: 77.4%–89.4%), for hereditary spherocytosis 
PPV was 80.6% (95% CI: 69.5%–88.9%), and for autoimmune hemolytic anemia PPV was 
78.4% (95% CI: 70.4%–85.0%).
Conclusion: The PPV of hemolytic anemias was moderately high. The PPVs were compa-
rable in the three main categories of overall hemolysis, and congenital and acquired hemolytic 
anemia.
Keywords: ICD-10 coding, diagnosis validation, hemoglobinopathy, spherocytosis, epidemiol-
ogy, congenital hemolytic anemia, acquired hemolytic anemia
Introduction
Hemolytic anemias and chronic hemolytic disorders are among the most prevalent 
congenital diseases with a major impact on health budgets around the world.1–7 Chronic 
anemia causes hypoxia and extra stress to cardiac function, and it may, as well, inflict 
negatively on the function of other organs.6,8 Individuals with anemia will most often 
suffer from headache, fatigue, dyspnea, impaired working ability, and impaired cognitive 
performance.6,8–10 Anemia has been reported to worsen prognosis and increase the cost 
of treatment of other diseases.6,11,12 Chronic hemolysis even without anemia has been 
reported to predispose to an increased risk of thrombotic disease and might predispose to 
infirmity and progressive morbidity.2,13–17 For some diseases with chronic hemolysis such 
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as paroxysmal nocturnal hemoglobinuria and sickle cell ane-
mia, an increased risk of thrombosis is well established.14,16,18,19 
In thalassemia a range of organ damage is well described, 
derived from hypoxia, thrombosis, and iron load.1,2,13
Denmark is, with its nationwide public health registers, an 
ideal place to evaluate morbidity associated with a disorder if 
the positive predictive value (PPV) of the primary diagnosis 
is known.20 All hospital-assigned diagnoses are registered in 
the Danish National Patient Register (DNPR) but the PPV 
of non-vitamin-deficiency hemolysis diagnoses has not been 
established prior to this time in the DNPR.21
In order to evaluate if registry-based diagnoses can be 
used to study morbidity in patients with chronic hemolysis, 
we studied the PPV of diagnosis coding for hemolytic ane-
mias in the DNPR.
Patients and methods
Patient cohort
We included all patients with a specialist outpatient clinic 
contact or inpatient admission at Odense University Hospital 
(OUH) registered in the DNPR with a first-ever diagnosis of 
hemolytic anemia from 1994 through 2012. This cohort was 
drawn from the DNPR and the Danish Civil Registration 
System (CRS). Every inhabitant of Denmark has a unique and 
permanent entry in the CRS – the civil registration number 
(CRN), allowing individual-level linkage across all public 
registers.20,22 The DNPR contains information on virtually all 
discharges from public hospitals since 1977 and on outpatient 
clinic visits since 1995.20,22 Denmark has very few private 
hospitals, none of which are involved in the diagnostic process 
of patients with hemolytic disorders. The data registered in 
the DNPR include the CRN dates of hospital outpatient visits, 
dates of hospital discharge, and up to 20 diagnoses coded by 
physicians according to the WHO International Classification 
of Diseases Tenth Revision (ICD-10) since 1994. Each hos-
pital contact is coded with the primary (first-listed) diagnosis 
that led to the hospital contact as well as secondary diagnoses, 
which the physician considers important in the care of the 
patient. The inclusion period was from January 1, 1994 to 
December 31, 2011. OUH has 1.1 million patient contacts per 
year and serves a population of 1.2 million inhabitants.
All patients with a diagnosis coding of a hemolytic 
disorder according to the ICD-10 in the DNPR (Tables S1 
and S2) who had been admitted for inpatient care or treated 
on an outpatient basis at OUH were considered for inclu-
sion, both when the hemolysis diagnosis was the first-listed 
diagnosis or any of the subsequent listed diagnoses. Patients 
with a new first-ever hemolysis diagnosis coding comprising 
erythrocyte membrane diseases, hemoglobinopathies, enzyme 
deficiencies, and acquired hemolytic diseases were included. 
Included diagnoses and counts can be seen in Table 1. As a 
first step, we excluded patients with a hemolytic disorder 
appearing before January 1, 1994 by means of the ICD-8 
diagnosis coding (Tables S1 and S2). Since our goal was to 
study diagnoses with an erythrocyte-specific cause of hemo-
lysis, patients with a mechanical reason for hemolysis such 
as an artificial heart valve and patients with either vitamin-
B12 or folic acid deficiency were also excluded. The ICD-8 
and ICD-10 coding used to define our target population is 
presented in Tables S1 and S2.
Medical record review
The cohort of patients with a hemolysis diagnosis code was 
drawn from the DNPR. For the review process, it was divided 
into two groups based on the registered diagnoses. Patient files 
with a diagnosis code in the DNPR suggestive of a hemoglo-
binopathy were reviewed by Ulrik Malthe Overgaard (UMO), 
the details of which are presented in the following section, 
while patients assigned diagnosis codes of all other hemolytic 
disorders were reviewed by Dennis Lund Hansen (DLH). This 
review included all the medical files and all available labora-
tory and pathology results. The medical files of the patients 
who after the initial review still had an unsolved hemolysis 
diagnosis were reevaluated by DLH and Henrik Frederiksen 
(HF) together. After this process, a final decision to either 
accept the original hemolysis diagnosis, or assign a new hemo-
lysis diagnosis, or judge the available material as insufficient 
for a causal hemolytic diagnosis was made. The workflow and 
results are illustrated in the flowchart (Figure 1).
Prior to the review of the medical records, an entry module 
was created in Epidata 3.1 containing ID number, date of birth, 
date of diagnosis coding for hemolysis, diagnosis code, up to 
15 signs and symptoms of hemolysis, ethnicity, gene and flow 
cytometry test results, a post-review best fitting diagnosis, and 
the date of the post-review diagnosis, defined as the date where 
the last test needed to make a causal diagnosis was available.23
Review of biochemical data
Laboratory diagnostics of hemoglobinopathies in Denmark 
is centralized at the Centre for Haemoglobinopathies, 
Department of Haematology, Herlev Hospital, University of 
Copenhagen, which performs almost all hemoglobinopathy 
analyses. The department has filed all laboratory results since 
May 1995. The database contains information of hemoglobin 
electrophoresis (currently performed as high-pressure liquid 
chromatography) and sequencing of alpha- and beta-globin
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genes by polymerase chain reaction (PCR) methods as previ-
ously described.24 All patients with a DNPR registration with 
a diagnosis of hemoglobinopathies were extracted from the 
complete DNPR cohort and were reviewed by UMO using 
this database. Patients with a hemoglobinopathy diagnosis 
code who were not registered in this database or did not 
have a confirmed hemoglobinopathy diagnosis proceeded 
to ordinary review of the medical files as described earlier 
in (Medical record review) section.
Criteria for diagnosis
In all patients, the biochemical verification of hemolysis 
was assessed first, with a subsequent validation of specific 
hemolytic diagnoses. Anemia was defined as hemoglobin 
concentration below 12.88 g/dL for men and 11.27 g/dL for 
women. For patients ,16 years, anemia was defined when 
hemoglobin was below the age-adjusted reference intervals. 
Hemolysis was defined as an increased count of reticulocytes 
combined with biochemical sign of erythrocyte destruction. 
The latter was defined when two of the following criteria 
were present: 1) increased lactate dehydrogenase above upper 
reference value, 2) decreased haptoglobin, 3) elevated free 
hemoglobin, or 4) hyperbilirubinemia.17,25–27 It was a prereq-
uisite that there was not a better explanation to the signs of 
hemolysis eg, liver disease.17,25–27 The diagnostic criteria for 
each of the causal hemolytic disorders were according to the 
published criteria and are presented in Tables 2 and 3.
Hereditary spherocytosis
Validating the medical files for patients who were coded 
with, or where a review of the medical files suggested, 
hereditary spherocytosis (HS) was a special challenge. 
Table 1 Diagnosis overview
ICD-10 Extracted 
diagnoses (%)
Herlev 
database
Primary 
review
Secondary 
review
Total 
verified
D550 – (G6PD) deficiency – 0 2 0 2
D552 – (PK) deficiency – 0 1 0 1
D56 – Thalassemia 130 (31.55) 8 20 8 36
D560 – Alpha-thalassemia – 19 4 0 23
D561 – Beta-thalassemia – 41 1 1 43
D563 – Thalassemia trait – 0 5 0 5
D57 – Sickle cell anemia 25 (6.07) 0 3 1 4
D572 – Double heterozygous sickling disorders – 2 0 0 2
D572a – Hb-SC disease – 4 1 0 5
D572d – Sickle cell thalassemia – 5 1 0 6
D573 – Heterozygous hemoglobin S – 6 0 0 6
D580 – Hereditary spherocytosis (HS) 72 (17.48) – – – –
D580 – HS, cat 0 – 0 36 8 44
D580 – HS, cat 1a – 0 0 3 3
D580 – HS, cat 1b – 0 0 2 2
D580 – HS, cat 1c – 0 0 9 9
D580 – HS, cat 2 – 0 0 7 7
D581 – Hereditary elliptocytosis 1 (0.24) 0 1 0 1
D582 – Other hemoglobinopathies 2 (0.49) 0 2 1 3
D582e – Hb-E disease – 3 0 1 4
D589 – Hereditary hemolytic anemia, unspecified 19 (4.61) 0 0 1 1
D590 – Drug-induced AiHA 5 (1.21) 0 1 1 2
D591 – AiHA, endogenous 129 (31.31) 0 80 15 95
D591a – Cold agglutinin 5 (1.21) 0 16 3 19
D592 – Drug-induced non-AiHA 4 (0.97) 0 1 1 2
D594 – Other non-AiHA 14 (3.40) 0 7 1 8
D594c – Toxic hemolytic anemia 1 (0.24) 0 0 0 0
D595 – Paroxysmal nocturnal hemoglobinuria 5 (1.21) 0 4 0 4
D599 – Acquired hemolytic anemia, unspecified – 0 9 9 18
Uncertain diagnosis – 0 0 20 20
No hemolytic disorder – 0 35 2 37
Total 412 88 230 94 412
Note: The lowercase suffix on D572, D582, D591, and D594 is a specific part of the Danish implementation of ICD-10.
Abbreviations: ICD-10, International Classification of Diseases Tenth Revision; G6PD, glucose-6-phosphate dehydrogenase; PK, pyruvate kinase; cat, category; AIHA, 
autoimmune hemolytic anemia; Hb-SC, sickle cell–haemoglobin C; Hb-E, hemoglobin E.
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The disease has a high prevalence in Northern Europe of 
2:10,000 to 3:10,000, and up to 1% of the population if 
milder or subclinical cases are included.28,29 An HS diagno-
sis is therefore often made in local hospitals without special-
ized hematological expertise. Our review was restricted to 
the medical record from our university hospital including 
the pathological record. Not all older local medical records 
were available. The review of HS diagnostic criteria (Table 
4) was made in accordance with literature.30–33 The diagno-
sis was based on the presence of hemolysis and additional 
criteria. Typically, patients were diagnosed based on fam-
ily history of hemolysis, negative direct antiglobulin test 
(DAT), and increased osmotic fragility or positive eosin-
5′-maleimide (EMA) binding test. The negative DAT was 
Study population, n=412
Biochemical
database
review, n=151
Unresolved, n=63 Primary review, n=324
Verified hemolysis
Hemolytic anemia, n=88 No hemolytic disorder, n=35
Hemolytic anemia, n=195
Hemolytic anemia, n=72
Secondary review, n=94
No hemolytic disorder, n=2
Uncertain diagnosis, n=16Uncertain diagnosis, n=4
Figure 1 Numbers of patients with extracted and verified diagnosis of hemolytic anemia.
Notes: The hexagons represent reviews. The patients from the cohort with a prior hemoglobinopathy diagnosis were first reviewed in the database for former positive tests 
for hemoglobinoathy at Herlev Hospital. Unresolved cases proceeded along with the nonhemoglobinopathy patients to the primary and if necessary secondary review.
Table 2 Definition of congenital hemolytic diseases
Disease ICD-10 Core criteria
Congenital
Thalassemia D56 Positive hemoglobin electrophoresis/HPLC and/or gene test
Sickle cell anemia D57 Positive hemoglobin electrophoresis/HPLC and confirmatory gene test
Hereditary spherocytosis D588 Hemolysis + reticulocytosis + family history of hemolysis + negative antiglobulin test + 
increased osmotic fragility or positive EMA test.
Hereditary elliptocytosis D581 increased osmotic fragility, elliptocytes, and family history
Other hemoglobinopathies D582 Positive hemoglobin electrophoresis/HPLC or gene test
Hereditary hemolytic anemia, unspecified D589 Hemolysis + anemia + family history or congenital lifelong hemolysis and no better explanation 
available
Abbreviations: ICD-10, International Classification of Diseases Tenth Revision; HPLC, high-pressure liquid chromatography; EMA, eosin-5′-maleimide.
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considered obligatory to the diagnosis, but if the patient 
was of Scandinavian ethnicity (and thereby “high risk”), 
negative family history or lack of increased osmotic fragility 
was accepted if other characteristics were present such as 
spherocytes and splenomegaly combined with normaliza-
tion of hemolysis after splenectomy (Table 4). DAT is part of 
the routine workup in patients with hemolysis, but negative 
DAT results are not always reported. In the HS category 2, 
we therefore assume that the DAT was done, and found to 
be negative, since no treatment applicable to autoimmune 
hemolytic anemia (AIHA) was used. Also, when the anemia 
is mild and there are no factors predisposing to AIHA such 
as malignancies and autoimmune diseases, the probability 
of AIHA is much smaller compared to the probability of 
HS.26,28,32,34–36
Ethics
The study was approved by the Danish Health and Medicines 
Authority in accordance with current Danish law (Reference 
number: 3-3013-307/1). In compliance with Danish law, the 
project was approved by the Danish Data Protection Agency 
through the Odense university hospital (Ref no 2008-58-
0035). Because this study was based on data extracted from 
registries, it was exempt from human subjects review, and 
members of the study population did not have to provide 
informed consent.
Statistical analysis
We used the original diagnosis based on the DNPR-registered 
ICD-10 diagnosis code and the subsequent review diagno-
sis to compute PPVs for categories of overall hemolysis 
Table 3 Definition of acquired hemolytic diseases
Disease ICD-10 Core criteria Supplementary criteria
Acquired
Drug-induced autoimmune and 
nonautoimmune hemolytic anemia
D590 + D592 Onset correlated with new medicine, and vanished 
after discontinuation and no prior history of hemolysis; 
preferably provocation test
if D590, preferably 
presence of antibodies
Autoimmune hemolytic anemia D591 Presence of erythrocyte antigen-specific 
autoantibodies
Concomitant sensitization 
with C3d
Chronic cold hemagglutinin disease D591a Presence of cold-type autoantibodies Sensitization only with C3d
Other nonautoimmune hemolytic anemias D594 Presence of schistocytes and relevant cause (eg, 
sarcoma) and symptoms abate after removal of 
potential cause
Toxic hemolytic anemia D594a Presence of potential hemolytic toxin and symptoms 
abate after removal of potential cause
Paroxysmal nocturnal hemoglobinuria D595 Presence of CD59- and CD55-deficient erythrocytes 
and granulocytes/monocytes by flow cytometry of 
peripheral blood
Acquired hemolytic anemia, unspecified D599 Hemolysis + anemia + known onset and no better 
explanation available
No family history
Note: The lowercase suffix on D591 and D594 is a specific part of the Danish implementation of ICD-10.
Abbreviation: ICD-10, International Classification of Diseases Tenth Revision.
Table 4 Categories of hereditary spherocytosis
Category Probability of hereditary spherocytosis Criteria
0 Definite Hemolysis, reticulocytosis, family history of hemolysis (preferably exact diagnosis 
in first-degree relative), negative antiglobulin test, and increased osmotic fragility 
or positive EMA test
1 Probable A. Hemolysis, reticulocytosis, negative antiglobulin test, spherocytes, 
Scandinavian ethnicity and no better explanation, or
B. Highly increased osmotic fragility, reticulocytosis, negative antiglobulin test, 
Scandinavian ethnicity and no better explanation, or
C. Hemolysis splenomegaly and splenectomy, negative antiglobulin test, 
spherocytosis, Scandinavian ethnicity and no better explanation
2 Likely Cases fitting category 0, or 1A–C but missing data on one of the following: 
antiglobulin test, family history, osmotic fragility test, or peripheral smear
Exclusion Unlikely Other well-defined hemolytic anemia or negative EMA test (when performed)
Abbreviation: EMA, eosin-5′-maleimide.
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congenital hemolysis, acquired hemolysis as well as for 
the specific hemolytic disorders, which included more than 
50 patients. Signs of coding errors were noted in the surgical 
departments where the hemolysis diagnosis was one character 
wrong, eg, C569: “Malignant neoplasm of ovary” and G560: 
“Carpal tunnel syndrome”, both mistyped as D56 alpha 
thalassemia. We therefore also repeated analyses excluding 
patients who only once were given a hemolysis diagnosis 
code and solely at a surgical department. For the group of 
patients with an “overall hemolysis” diagnosis, patients were 
included as a verified hemolytic disorder if the previously 
mentioned biochemical criteria for hemolysis were present, 
regardless of whether the specific causal hemolytic diagnosis 
code was correct. For the subgroups of specific hemolytic 
disorders, patients were assigned a causal hemolytic diag-
nosis if their symptoms and biochemical results matched 
one of the diagnostic criteria in Tables 2–4. The process was 
unblinded as the primary extraction diagnosis and the medi-
cal file were available.
PPVs and 95% confidence intervals (95% CIs) were 
calculated as the fraction of confirmed hemolytic diagnoses 
of the original DNPR-registered ICD-10 diagnosis coded 
cases. Medical files where the available data were insuffi-
cient to judge whether hemolysis and/or a causal hemolytic 
diagnosis was present were counted as not confirmed. The 
diagnosis of thalassemia and sickle cell anemia was also 
accepted if the true diagnosis was sickle cell (beta-)thalas-
semia (D572, denoted D572d in the Danish implementation 
of ICD-10). For patients with AIHA, patients with warm 
type, cold type, or mixed type autoantibodies were grouped 
together in the calculation of sensitivity and PPV (Table 5). 
The diagnosis of HS was accepted as confirmed when the 
post-review score was 0 or 1 (Table 4). The second category 
was included in some auxiliary calculations of PPV and 
age-stratified HS.
All statistics computing has been done in STATA version 
10.1 using the diagt command (package: sbe36 and sbe36_1) 
which reports PPV and calculates exact binomial confidence 
intervals.37
Results
Hemolysis
We identified 412 patients with a first-ever hemolysis diag-
nosis code at OUH during 1994–2011. Medical files from 
the time of the hemolytic diagnosis could be identified for all 
patients. Out of the 412 patients, there was no secure evidence 
of hemolysis in 53 patients and hemolysis was confirmed in 
359, yielding a PPV of 87.1% for hemolysis (83.6–90.2).
Thirty-seven patients were excluded as there was no 
evidence of hemolysis at any time in the record. Among an 
additional 20 patients, there was insufficient information in 
the medical file to make an exact diagnosis, however four of 
whom had sufficient information to confirm the presence of 
hemolysis. Thirteen of the 20 inconclusive files were from 
before 1999 when electronic medical records commenced. 
Some older paper medical records could not be retrieved. The 
overall proportion of patients with verified hemolysis was 
constant in the two time periods (1994–2002 and 2003–2011). 
In both the time periods, the proportion with verified hemo-
lysis was highest in the group below 18 years.
Diagnosis coding
Of the 359 patients who had biochemical verification 
of hemolysis, the initial diagnosis code was confirmed 
in 294 patients, yielding an overall PPV of 71.4% (95% 
CI: 66.7%–75.6%). If patients with clear signs of diagnosis 
code typing error from surgical departments were disregarded, 
the PPV increased to 74.2% (95% CI: 69.6%–78.5%), and if 
patients with a category 2 diagnosis of HS were included, an 
overall PPV of 76.0% (95% CI: 71.5%–80.1%) was achieved. 
The PPV values were identical for both sexes, but the PPV 
was much higher in patients below 19 years (97.9%) (95% 
CI: 93.9%–99.6%) compared to patients $19 years (81.6%) 
(95% CI: 76.4%–86.0%) (Table 6). In 20 patients with hemo-
lysis, not all files necessary for a causal diagnosis could be 
found and were therefore classified as insufficient for a causal 
diagnosis. If these patients were disregarded, the PPV in the 
age group above 18 years was computed to be 92.0% (95% 
CI: 87.8%–95.1%).
Congenital hemolytic anemia – all 
subtypes
We defined 249 patients as having congenital hemolytic ane-
mia due to their ICD-10 diagnosis codes (Tables S1 and S2). 
Hemolysis was confirmed in 216 (86.7%) and 197 patients 
could after review be confirmed as having congenital hemo-
lytic anemia. The 13 patients for whom the diagnosis was 
unconfirmed had anemia due to hematological malignancy 
(n=8) or lacked information (n=5). The overall predictive 
value of a diagnosis of congenital hemolytic anemia was 
79.1% (95% CI: 73.5%–84.0%). If patients with clear signs 
of typing error during diagnosis from surgical departments 
were disregarded (ten patients), the PPV increased to 83.8% 
(95% CI: 78.5–88.3). If category 2 of the HS diagnosis was 
included and the patients with clear signs of a mistyped one-
time diagnosis from surgical departments were disregarded, 
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Table 5 Table of results – PPV of specific diagnoses
ICD diagnosis Extraction Review Agreement Disagreement PPV
Congenital hemolysis
  Congenital hemolysis 249 200 197 52 79.1 (73.5–84.0)
  Congenital hemolysis, nonsurgical 235 200 197 38 83.8 (78.5–88.3)
    D55x Enzyme deficiencies
    D56x Thalassemia
    D57x Sickle cell anemia
    D582x Other hemoglobinopathies
    D580 Hereditary spherocytosis (0–1)
    D581a Hereditary elliptocytosis
    D582x Other hemoglobinopathies
    D588 Other hereditary hemolytic anemia
    D589 Hereditary hemolytic anemia
    Hemoglobinopathies 157 137 132 25 84.1 (77.4–89.4)
    Hemoglobinopathies, nonsurgical 144 137 132 12 91.7 (85.9–95.6)
    D56x Thalassemia
    D57x Sickle cell anemia
    D582x Other hemoglobinopathies
    D56 Thalassemia 130 113 107 23 82.3 (74.7–88.4)
    D56 Thalassemia, nonsurgical 122 113 107 15 87.7 (80.5–93.0)
    D56 Thalassemia 36
    D560 Alpha-thalassemia 23
    D561 Beta-thalassemia 43
    D563 Thalassemia minor 5
    D572d Sickle cell thalassemia 6
    D57 Sickle cell anemia 25 23 18 7
    D57 Sickle cell anemia 4
    D572 Double heterozygous sickling disorders 2
    D572a Hb-SC disease 5
    D572d Sickle cell thalassemia 6
    D573 Heterozygous hemoglobin S 6
    D580 Hereditary spherocytosis (0–1) 72 58 51 21 70.8 (58.9–81.0)
    D580 Hereditary spherocytosis (0–2) 72 65 58 14 80.6 (69.5–88.9)
    D581a Hereditary elliptocytosis 1 1 1 0
    D582 Other hemoglobinopathies 2 7 1 1
    D582 Other hemoglobinopathies 3
    D582e Hb-E disease 4
    D588 Other hereditary hemolytic anemia 2 0 0 2
    D589 Hereditary hemolytic anemia, unspecified 17 1 0 17
Acquired
  Acquired hemolysis 163 148 136 27 83.4 (76.8–88.8)
    D590 AiHA, drug-induced 2
    D591x Other AiHA, non-drug-induced 13
    D592 Hemolytic nonautoimmune anemia 2
    D594x Other hemolytic nonautoimmune 7
    D595 Paroxysmal nocturnal hemoglobinuria 4
    D598 Other acquired hemolytic anemia 5
    D599 Acquired hemolytic anemia, unspecified 3
    D590 AiHA, drug-induced 5 2 0 5
    D591 AIHA, not drug-induced 134 114 105 29 78.4 (70.4–85.0)
    D591a Cold-agglutinin disease 19
    D592 Hemolytic nonautoimmune anemia 4 2 2 2
    D594 Other hemolytic nonautoimmune 14 8 5 9
    D594c Toxic hemolytic anemia 1 0 0 1
    D595 Paroxysmal nocturnal hemoglobinuria 5 4 4 1  
Notes: The lowercase suffix on D572, D582, D591, and D594 refers to the specific Danish implementation of ICD-10 using lowercase letters to denote subtypes. Bold 
figures refer to classification lines (congital versus acquired) and major subgroups (congenital all forms, all forms of hemoglobinopathies thalassemia, sickle cell anaemia, and 
spherocytosis, all forms of acquired hemolysis and AiHA [not drug-induced]).
Abbreviations: ICD-10, International Classification of Diseases Tenth Revision; AIHA, autoimmune hemolytic anemia; PPV, positive predictive value; Hb-SC, sickle cell–
hemoglobin C; Hb-E, hemoglobin E.
Clinical Epidemiology 2016:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
247
Positive predictive value of hemolytic anemia
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
25
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
204 of the initial 249 patients were confirmed after review 
as having congenital hemolytic anemia, yielding a PPV of 
86.8% (95% CI: 81.8%–90.9%). The predictive value of all 
hemoglobinopathies was 84.1% (95% CI: 77.4%–89.4%) 
and for thalassemia, in particular, it was 82.3% (95% CI: 
74.7–88.4). Further results are listed in Table 5.
Hereditary spherocytosis
Of the original 412 patients, 72 were coded with a diagnosis 
of HS. In general, a more severe disease with symptomatic 
anemia triggered a more complete diagnostic approach 
and a reliable diagnosis (data not shown). After review, ten 
cases did not comply with HS. These patients had iron-
deficiency anemia due to bleeding (two patients), anemia 
due to end-stage liver disease (two patients), showed no 
signs of hemolysis or had missing information in the medi-
cal files (three patients), anemia due to inflammation (two 
patients), and one patient had AIHA. With the most restrictive 
approach with only categories 0 to 1 accepted as HS diag-
noses, the PPV was 70.8% (95% CI: 58.9%–81.0%). When 
the categories 0 to 2 were accepted, the PPV increased to 
80.6% (95% CI: 69.5%–88.9%). An additional two patients 
fulfilled all the criteria for HS, but since their EMA test 
was negative, we categorized these patients as HS negative, 
due to the very high reliability of this test.30 In two patients, 
medical files were very suggestive of an HS diagnosis. 
However, this could not be finally confirmed due to lack of 
sufficient information in one and alcohol abuse and liver 
disease obscuring the definite hemolytic diagnosis in the 
other. If these two suspected cases are accepted as HS, 
a PPV of 83.3% (95% CI: 72.7%–91.1%) was obtained.
The diagnosis coding of HS was most reliable for younger 
people since the PPV among patients #18 years was 84.6% 
(95% CI: 69.5%–94.1%) for categories 0 to 1 HS diagnosis. 
Table 6 Table of results – overall hemolysis
ICD diagnosis Extraction Review Agreement Disagreement PPV
1994–2011
Overall hemolysis 412 359 359 53 87.1 (83.5–90.2)
 Male (all ages) 178 158 158 20 88.8 (83.2–93.0)
 Female (all ages) 234 201 201 33 85.9 (80.8–90.1)
 Male, female 0–18 (Y) 141 138 138 3 97.9 (93.9–99.6)
 Male, female 18+ (Y) 271 221 221 50 81.6 (76.4–86.0)
Overall hemolysis, nonsurgical 396 359 359 37 90.7 (87.4–93.3)
 Male, nonsurgical (all ages) 169 158 158 11 93.5 (88.7–96.7)
 Female, nonsurgical (all ages) 227 201 201 26 88.6(83.7–92.4)
 Male, female 0–18 (Y), nonsurgical 141 138 138 3 97.9 (93.9–99.6)
 Male, female 18+ (Y), nonsurgical 255 221 221 34 86.7 (81.9–90.6)
1994–2002
Overall hemolysis 145 124 124 21 85.5 (78.7–90.8)
 Male (all ages) 69 63 63 6 91.3 (82.0–96.7)
 Female (all ages) 76 61 61 12 80.3 (69.5–88.5)
 Male, female 0–18 (Y) 59 56 56 3 94.9 (85.9–98.9)
 Male, female 18+ (Y) 86 68 68 18 79.1 (69.0–87.1)
Overall hemolysis nonsurgical 139 124 124 15 89.2 (82.8–93.8)
 Male, nonsurgical (all ages) 66 63 63 3 95.4 (87.3–99.1)
 Female, nonsurgical (all ages) 73 61 61 12 83.6 (73.1–91.2)
 Male, female 0–18 (Y), nonsurgical 59 56 56 3 94.9 (85.9–98.9)
 Male, female 18+ (Y), nonsurgical 80 68 68 12 85.0 (75.3–92.0)
2003–2011
Overall hemolysis 267 235 235 32 88.0 (83.5–91.7)
 Male (all ages) 109 95 95 14 87.2 (79.4–92.8)
 Female (all ages) 158 140 140 18 88.6 (82.6–93.1)
 Male, female 0–18 (Y) 82 82 82 0 100 (95.6–100)
 Male, female 18+ (Y) 185 153 153 32 82.7 (76.5–87.9)
Overall hemolysis nonsurgical 257 235 235 22 91.4 (87.3–94.6)
 Male, nonsurgical (all ages) 103 95 95 8 92.2 (85.3–96.6)
 Female, nonsurgical (all ages) 154 140 140 14 90.9 (85.2–94.9)
 Male, female 0–18 (Y), nonsurgical 82 82 82 0 100 (95.6–100)
 Male, female 18+ (Y), nonsurgical 175 153 153 22 87.4 (81.6–92.0)
Notes: Values in parenthesis denote 95% CI. Bold figures refer to subgroups according to time period and diagnosis made in non-surgical departments.
Abbreviations: ICD-10, International Classification of Diseases Tenth Revision; PPV, positive predictive value; CI, confidence interval; Y, year.
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For patients above 18 years, the PPV was 54.6% (95% 
CI: 36.4%–71.9%) for categories 0 to 1. If category 2 (likely 
HS) is included as verified HS diagnoses, the PPVs increase 
to 92.3% (95% CI: 79.1%–98.4%) for patients #18 years 
and 66.7% (95% CI: 48.2%–82.0%) for patients .18 years. 
Six patients who after review were diagnosed with HS were 
a priori misclassified as acquired hemolytic anemia (n=2) or 
“other hereditary hemolytic anemia” (n=4).
Acquired hemolytic anemia
In 163 patients (37.9%), the ICD-10 diagnosis code was 
acquired hemolytic anemia (Tables S1 and S2). After the 
review of medical files, there was evidence of hemolysis in 
143 (84.7%) patients and the diagnosis was confirmed in 
136 patients, yielding an overall predictive value of 83.4% 
for acquired hemolysis (95% CI: 76.8%–88.8%). The 27 
non-confirmed cases consisted of eleven patients without 
any sign of a hemolytic disorder such as iron deficiency 
anemia, 13 patients with insufficient medical information for 
a specific diagnosis, and three patients misclassified as HS. 
Of the 13 with insufficient information, four had biochemical 
signs of hemolysis. Among the 111 patients (82%) who had 
confirmed acquired hemolytic anemia, the causal diagnosis 
was non-drug-induced AIHA, of whom 19 patients (17%) 
could be ascribed to cold agglutinin syndrome, 48 patients 
(43%) had warm-antibody-mediated AIHA, and the remain-
ing 44 cases (40%) were either mixed type or were lacking 
information on type. One patient had no detectable antibodies 
or complement binding, but had symptoms, biochemistry, 
and treatment response identical to AIHA and was classi-
fied as AIHA without detectable antibodies (DAT-negative 
AIHA).36,38 The PPV for non-drug-induced AIHA was 78.4% 
(95% CI: 70.4%–85.0%). PPV of other subtypes was not 
calculated due to low prevalence.
Discussion
The overall PPV of a hemolysis diagnosis varied from ∼80% 
to 98% for some subtypes and categories. The lowest PPV was 
found in the older age group. This may be due to the fact that 
all the medical files could not be retrieved for patients who 
were deceased. Although we excluded patients with an older 
diagnosis code of hemolytic anemia, our search could not 
exclude patients with a hemolytic anemia diagnosed prior to 
the establishment of the DNPR in 1973 if the diagnosis cod-
ing was reassigned after 1994. Therefore, our data included 
at least 6% among the older population where the diagnosis 
code of hemolytic anemia was not a conclusion of a recent 
diagnostic process but merely referred information of previous 
medical files, and where the original diagnostic workup and 
result were no longer available. This is probably the main 
reason for the lower PPV (81.6%) in the older age group, 
since PPV among older patients with current available medical 
files was nearly as high as in the younger age groups; 92.0% 
and 97.9%, respectively. As the prevalence of all hemolytic 
disorders is unknown, we cannot evaluate the coverage of our 
data, and we do therefore not know the undiagnosed propor-
tion of patients with hemolytic disorder. The overall PPV of 
87.1% for hemolysis was comparable to the proportion of 
documented hemolysis in the group of congenital hemolysis 
(86.7%) and the group of acquired hemolysis (84.7%). In the 
combined disease specific groups with congenital hemolytic 
anemia and acquired hemolytic anemia the PPVs were slightly 
lower. This suggest that ongoing hemolysis will be diagnosed 
as such, but not always be given the correct causal disease or 
diagnosis coding.
Congenital hemolytic anemia
The prevalence of hemolysis within the group of a priori 
labeled congenital hemolytic anemia was about 90%, equal 
to overall prevalence of hemolysis in the entire cohort, sup-
porting the assumption that a diagnosis of hemolysis is not 
assigned without biochemical evidence of hemolysis. All 
the 16 patients for whom the correct diagnosis strongly sug-
gested a mistyping of the diagnosis code appeared only once 
in the DNPR, and all from the surgical departments which 
would usually not be involved in the diagnostic process of 
a hemolytic anemia.
The high PPV of the specific diagnosis reflects that the 
majority of these patients had a hemoglobinopathy often with 
anemia since childhood, thereby demanding an extensive 
workup to establish a causal diagnosis, and a high alertness 
of the clinician, due to prevailing family history. Similarly, 
18 of the 20 cases with insufficient information to make 
a definite review diagnosis were seen among patients above 
18 years – where the medical file with the original diagnostic 
workup could not be retrieved.
Hereditary spherocytosis
Among the patients who were finally defined as cases of HS, 
10% were a priori misclassified as other subtypes of hemo-
lytic anemia. In general, a more severe symptomatic anemia 
triggered a more complete diagnostic approach, and it is 
therefore likely that the probability of a correct HS diagnosis 
is increases with the severity of the disease. The problem of 
incomplete diagnostic approaches in HS triggered a division 
of patients into different categories. The fourth category was 
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established on the assumption that one of the four symptoms 
(increased osmotic fragility, family history, spherocytosis, 
and negative DAT) could be missing in typical cases, without 
jeopardizing the definite HS diagnosis. Increased osmotic 
fragility is not present in all cases of HS, and this information 
could be missing, if everything else fitted.30 Spherocytes are 
reported to be present in nearly all patients, but are regarded 
as an unspecific sign by the pathologists and are therefore not 
always reported in the description of the blood smear.29,30,34 
A positive family history for hemolysis is only present in 80% 
of the HS patients.29–33
The most critical aberration from the definitions was a 
missing DAT, since the most important differential diag-
nosis is AIHA due to the presence of spherocytosis in both 
diseases.26,32,33,35,36,38
Acquired hemolytic anemia
Among the patients with a diagnosis code of an acquired 
hemolytic disorder, 84% were confirmed and 4% had 
ongoing hemolysis without a definite causal diagnosis. The 
remaining 12% did not have any signs of a hemolytic disor-
der. The resulting PPV is comparable to the overall PPV of 
hemolysis and makes this subgroup a reliable entity in the 
DNPR. This supports our impression that a diagnosis code of 
hemolysis is not assigned without biochemical evidence. The 
high PPV of an AIHA diagnosis can probably be ascribed to 
the relatively simple diagnostic procedure based on hemolysis 
and a positive DAT. Approximately, 3%–5% of AIHA patients 
have been reported to have a negative DAT and this small 
fraction is likely to be either misclassified or underreported 
in registries due to this negative test result.35,36,38
Strengths and limitations
Our study was based on a review of a large number of patients 
with hemolytic disorders and with more than 95% complete-
ness of retrieval of medical files. It is a limitation that it is 
based on patients from one university hospital. In spite of 
this, a large number of patients had begun the diagnostic 
process or were already diagnosed at a primary hospital 
and our study thus reflects the accuracy of the diagnosis in 
the health care region indirectly. There is a risk, however, 
that primarily the severely affected and more thoroughly 
examined patients are referred to the university hospital, and 
the proportion of misdiagnosed patients could be higher in 
the entire population. As many of the laboratory tests are 
centralized at Herlev Hospital, the high PPVs for hemoglo-
binopathy should account for the entire country. The study 
relies on both the doctors’ ability to make the right diagnosis 
and the registration of all Danish patients in the DNPR. If 
the results are accepted as a proxy for the doctors’ ability in 
making the correct diagnosis, then the results should be at 
least partly generalizable to comparable hospitals in other 
countries, but the coverage may vary with different types of 
health care systems.
Our review process was rigid; all records on patients who 
did not have a positive electrophoresis or genetic test in the 
database at Herlev Hospital were read by the same person. All 
patients with non-classical presentations were evaluated by 
both DLH and HF, to ensure consistent decision making.
Our study design prohibited inclusion of patients with 
unregistered hemolysis, and it was not feasible to estimate 
the prevalence of hemolytic disorders among general 
patients at OUH. Therefore, the sensitivity and the nega-
tive predictive values of the hemolysis diagnosis could not 
be assessed.
Apart from the most restricted definition of HS where the 
PPV was 70.8%, all PPVs (overall, congenital, acquired, and 
larger subgroups) varied from 78.4% to 84.1%. The predic-
tive values are comparable to literature values for PPV in, eg, 
venous thromboembolism in adults (75%–85%), Monoclonal 
gammopathy of undetermined significance” (82.3%), and 
shock (86.1%).39–41 These findings support the possibility of 
future studies, but considerations on the diagnosis validity 
are needed in some subgroups.
There was evidence of typing errors, a problem also 
seen in other similar works, and a marked increase in PPV 
when cases with diagnoses from surgical departments were 
omitted.40 In future works, this approach should be considered 
as well as the possible inclusion of some nationwide labora-
tory records to rule out patients with normal blood tests.
Conclusion
The overall PPV of hemolysis in the cohort was 87.1%, higher 
in patients below 19 years of age and with a slight improvement 
over time. The PPVs from subgroups of hemolytic anemias range 
from 78.4% to 84.1% The PPV was comparable in the three 
main categories: overall hemolysis, congenital, and acquired 
hemolytic anemia. The difference in PPV between patients aged 
.18 and #18 years was mainly due to the lack of information 
in the older medical files and that severe anemia among children 
triggered a more extensive diagnostic workup.
The diagnosis of hemolytic disorders can be used for 
further register-based studies, with an acceptable reliability 
in both older and younger groups. The diagnosis of HS can 
be used with some precautions given the different definitions 
of the diagnosis.
Clinical Epidemiology 2016:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
250
Hansen et al
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
25
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Author contributions
All authors contributed toward data analysis, drafting and 
critically revising the paper and agree to be accountable for 
all aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Cappellini M-D, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. 
Guidelines for the Clinical Management of Thalassaemia. 2nd ed. 
Nicosia, Cyprus: Thalassaemia International Federation (TIF); 2008.
 2. Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V. Guide-
lines for the Management of Non Transfusion Dependent Thalassaemia 
(NTDT). Nicosia, Cyprus: Thalassaemia International Federation (TIF); 
2013.
 3. Inati-Khoriaty A. Sicle Cell Disease. Nicosia, Cyprus: Thalassaemia 
International Federation (TIF); 2008.
 4. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global burden 
of sickle cell anaemia in children under five, 2010–2050: modelling 
based on demographics, excess mortality, and interventions. PLoS Med. 
2003;10:1–14.
 5. Weatherall D. The inherited disorder of haemoglobin: an increas-
ingly neglected global health burden. Indian J Med Res. 2011;134: 
493–497.
 6. Smith RE. The clinical and economic burden of anemia. Am J Manag 
Care. 2010;16(Suppl Issues):S59–S66.
 7. Amato A, Grisanti P, Mastropietro F, et al. Epidemiology and screen-
ing of sickle cell anemia in the Mediterranean area and in developing 
countries. Ig Sanita Pubbl. 2014;70(1):41–52.
 8. Schaffalitzky de Muckadell OB, Haunsø S, Vilstrup H. Medicinsk 
kompendium [Medical Compendium]. 17th ed. Kbh.: Nyt Nordisk Forlag 
Arnold Busck; 2009.
 9. Lozoff B, Beard J, Connor J, Felt B, Georgieff M, Schallert T. Long-
lasting neural and behavioral effects of iron deficiency in infancy. Nutr 
Rev. 2006;64(5 Pt 2):S34–S91.
 10. Andro M, Le Squere P, Estivin S, Gentric A. Anaemia and cognitive 
performances in the elderly: a systematic review. Eur J Neurol Off J 
Eur Fed Neurol Soc. 2013;20(9):1234–1240.
 11. Clevenger B, Richards T. Pre-operative anaemia. Anaesthesia. 
2015;70(Suppl 1):20–28. 
 12. Kansagara D, Dyer E, Englander H, Fu R, Freeman M, Kagen D. Treat-
ment of anemia in patients with heart disease: a systematic review. Ann 
Intern Med. 2013;159(11):746–757.
 13. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz E. Non- transfusion-
dependent thalassemias. Haematologica. 2013;98:833–844.
 14. Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal 
hemoglobinuria. Blood. 2013;121:4985–4996.
 15. Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of 
intravascular hemolysis and extracellular plasma hemoglobin: a novel 
mechanism of human disease. JAMA. 2005;293(13):1653–1662.
 16. De FL, Cappellini M-D, Olivieri O. Thrombosis and sickle cell disease. 
Semin Thromb Hemost. 2011;37:226–236.
 17. L’Acqua C, Hod E. New perspectives on the thrombotic complications 
of haemolysis. Br J Haematol. 2015;168(2):175–185.
 18. Van Bijnen ST, Van Heerde WL, Muus P. Mechanisms and clinical 
implications of thrombosis in paroxysmal nocturnal hemoglobinuria. 
J Thromb Haemost. 2012;10:1–10.
 19. Switzer JA, Hess DC, Nichols FT, Adams RJ. Pathophysiology and 
treatment of stroke in sickle-cell disease: present and future. Lancet 
Neurol. 2006;5:501–512.
 20. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient 
Register. Scand J Public Health. 2011;39(Suppl 7):30–33.
 21. Ghezala IB, Arendt JFB, Erichsen R, et al. Positive predictive value of 
the diagnosis coding for vitamin B12 deficiency anemia in the Danish 
National Patient Register. Clin Epidemiol. 2012;4:333–338.
 22. Pedersen CB. The Danish Civil Registration System. Scand J Public 
Health. 2011;39(Suppl 7):22–25.
 23. Lauritsen JM, ed. EpiData Data Entry, Data Management and Basic 
Statistical Analysis System. EpiData Assoc. 2000–2008. Available from: 
http://www.epidata.dk. Accessed on March 21, 2015.
 24. Kornblit B, Hagve TA, Taaning P, Birgens H. Phenotypic presentation 
and underlying mutations in carriers of beta-thalassaemia and alpha-
thalassaemia in the Danish immigrant population. Scand J Clin Lab 
Invest. 2007;67(1):97–104. 
 25. Marchand A, Galen RS, Van Lente F. The predictive value of serum 
haptoglobin in hemolytic disease. JAMA. 1980;243(19):1909–1911.
 26. Schrier S. Approach to the diagnosis of hemolytic anemia in the adult. 
Available from: http://www.uptodate.com/contents/approach-to-the-
diagnosis-of-hemolytic-anemia-in-the-adult?source=search_result
&search=hemolysis&selectedTitle=1%7E150. Accessed March 21, 
2015.
 27. Ballas SK. Lactate dehydrogenase and hemolysis in sickle cell disease. 
Blood. 2013;121(1):243–244.
 28. Eber SW, Pekrun A, Schröter W. Prevalence of increased osmotic fragil-
ity of erythrocytes in German blood donors: screening using a modified 
glycerol lysis test. Ann Hematol. 1992;68:88–92.
 29. Eber S, Lux SE. Hereditary spherocytosis—defects in proteins that 
connect the membrane skeleton to the lipid bilayer. Semin Hematol. 
2004;41:118–141.
 30. Bianchi P, Fermo E, Vercellati C, et al. Diagnostic power of laboratory 
tests for hereditary spherocytosis: a comparison study in 150 patients 
grouped according to molecular and clinical characteristics. Haema-
tologica. 2012;97(4):516–523.
 31. King M-J, Garçon L, Hoyer JD, et al. ICSH guidelines for the laboratory 
diagnosis of nonimmune hereditary red cell membrane disorders. Int 
J Lab Hematol. 2015;37(3):304–325. 
 32. Bolton-Maggs PHB, Langer JC, Iolascon A, Tittensor P, King MJ, 
General Haematology Task Force of the British Committee for 
Standards in Haematology. Guidelines for the diagnosis and man-
agement of hereditary spherocytosis – 2011 update. Br J Haematol. 
2012;156(1):37–49.
 33. King MJ, Zanella A. Hereditary red cell membrane disorders 
and laboratory diagnostic testing. Int J Lab Hematol. 2013;35: 
237–243.
 34. Baandrup U. Klinisk patologi [Clinical Pathology]. Copenhagen, Den-
mark: FADL; 2002.
 35. Zantek ND, Koepsell SA, Tharp DR, Cohn CS. The direct antiglobu-
lin test: a critical step in the evaluation of hemolysis. Am J Hematol. 
2012;87(7):707–709.
 36. Barcellini W, Fattizzo B, Zaninoni A, et al. Clinical heterogene-
ity and predictors of outcome in primary autoimmune hemolytic 
anemia: a GIMEMA study of 308 patients. Blood. 2014;124(19): 
2930–2936. 
 37. StataCorp. Stata Statistical Software: Release 10. College Station, TX: 
StataCorp LP; 2007.
 38. Zanella A, Barcellini W. Treatment of autoimmune hemolytic anemias. 
Haematologica. 2014;99(10):1547–1554.
 39. Gregersen H, Larsen CB, Haglund A, Mortensen R, Andersen NF, 
Nørgaard M. Data quality of the monoclonal gammopathy of unde-
termined significance diagnosis in a hospital registry. Clin Epidemiol. 
2013;5:321–326.
 40. Tuckuviene R, Kristensen SR, Helgestad J, Christensen AL, Johnsen SP. 
Predictive value of pediatric thrombosis diagnoses in the Danish 
National Patient Registry. Clin Epidemiol. 2010;2:107–122.
 41. Lauridsen MD, Gammelager H, Schmidt M, Nielsen H, Christiansen CF. 
Positive predictive value of International Classification of Diseases, 
10th revision, diagnosis codes for cardiogenic, hypovolemic, and septic 
shock in the Danish National Patient Registry. BMC Med Res Methodol. 
2015;15:23.
Clinical Epidemiology 2016:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
251
Positive predictive value of hemolytic anemia
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
25
-F
eb
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Table S1 included diagnoses
Included diagnoses ICD-10 code
Hereditary hemolysis
Enzyme deficiencies D55
(G6PD) deficiency, (PK) deficiency and 
others
Hemoglobinopathies
Thalassemia D56
Alpha-/Beta-thalassemia, thalassemia trait
Sickle cell anemia D57, M140c, N082c, 
H368c, M904
Other hemoglobinopathies D582
Erythrocyte membrane defects
 Hereditary spherocytosis D580
 Hereditary elliptocytosis D581
 Hereditary stomatocytosis D588a
 Other hereditary hemolytic anemia D588, D589
Acquired hemolysis
Autoimmune hemolytic anemia D591
Drug-induced immune and nonimmune hemolysis D590, D592
Cold-agglutinin disease D591a
Cold hemoglobinuria D596a
Other nonimmune hemolysis D594, D594c
Paroxysmal nocturnal hemoglobinuria D595
Note: The lowercase suffix is a specific Danish implementation of ICD-10 using 
lowercase letters to denote subtypes.
Abbreviations: G6PD, glucose-6-phosphate dehydrogenase; PK, Pyruvate kinase; 
ICD-10, International Classification of Diseases Tenth Revision.
Table S2 Excluded diagnoses
Excluded diagnoses ICD-8/ICD-10 code
iCD-8 diagnosis code of hemolysis 28209, 28219, 28229, 28230, 
28239, 28249, 28250, 28258, 
28259, 28299, 28390, 28391, 
28392, 28393, 28395, 28399, 
28649, 28659, 28690, 28699, 
44649, 99751, 390448
Vitamin-B12 deficiency D51
Folic acid deficiency D52
Cardiovascular disease including heart  
valve disease before and up to 1 year  
after index disease diagnosis date
Condition with artificial heart valve Z952, Z953, Z954
Mechanical hemolysis D594a
Note: The lowercase suffix is a specific Danish implementation of ICD-10 using 
lowercase letters to denote subtypes.
Abbreviation: ICD, International Classification of Diseases.
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